Thalidomide-O-amido-PEG3-C2-NH2 (TFA)

• UNSPSC Description:

  Thalidomide-O-amido-PEG3-C2-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology.

• Target Antigen:

  Apoptosis; Autophagy; E3 Ligase Ligand-Linker Conjugates

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;Autophagy;PROTAC

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/E3_ligase_Ligand-Linker_Conjugates_14.html

• Purity:

  99.55

• Solubility:

  DMSO : 50 mg/mL (ultrasonic)

• Smiles:

  O=C(N(C(CCC1=O)C(N1)=O)C2=O)C(C2=CC=C3)=C3OCC(NCCOCCOCCOCCN)=O.FC(F)(F)C(O)=O

• Molecular Weight:

  620.53

• References & Citations:

  [1]BRADNER, James, et al. METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES. WO2017024317A2.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, sealed storage, away from moisture)

• Clinical Information:

  No Development Reported

• CAS Number:

  1957236-21-3